3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Recurrence
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hematologic Diseases
1
Glioma
1
Blood Protein Disorders
1
Interventions
Dexamethasone
3
Cyclophosphamide
3
isatuximab
2
Lenalidomide
2
Bortezomib
2
pomalidomide
1
ofatumumab
1
fludarabine phosphate
1
fludarabine
1
epratuzumab
1
daratumumab
1
birtamimab
1
Whole-Body Irradiation
1
Thalidomide
1
Tacrolimus
1
Ranitidine
1
Mycophenolic Acid
1
Melphalan
1
Etoposide
1
Doxorubicin
1
Diphenhydramine
1
Cisplatin
1
Calcium Dobesilate
1
CLR1404
1
Acetaminophen
1
ARQ 197
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Paraproteinemias
×
CLR1404
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled